Business
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely
About this update from Nuvalent, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced upcoming poster presentations further characterizing the preclinical profiles of its novel ALK-selective inhibitor, neladalkib, and novel ROS1-selective inhibitor, zidesamtinib, at the American Association for Cancer Research (AACR) Annual Meeting 2025 from April 25-30, 2025, in Chicago.\n\n \n \n \n \n \n \n\n \nDetails of the poster presentations are as follows:\nTitle: Mutagenesis screens support potential best-in-class profile for neladalkib (NVL-655), a brain-penetrant and TRK-sparing ALK inhibitorAuthors: Anupong Tangpeerachaikul*1, Henry E. Pelish1Abstract Number: 1729Session Category: Experimental and Molecular Therapeutics Session Title: Kinase and Phosphatase Inhibitors 1Session Date and Time: April 28, 2025, from 9:00 a.m.– 12:00 p.m. CTLocation: Poster Section 21Poster Board Number: 4\nTitle: Crystal structure of drug-resistant ROS1 G2032R in complex with zidesamtinib, a clinical-stage ROS1 inhibitor with best-in-class potentialAuthors: Joseph M. Magrino*1, Anupong Tangpeerachaikul1, Scot Mente1, Henry E. Pelish1Abstract Number: 5616Session Category: Experimental and Molecular Therapeutics Session Title: Kinase and Phosphatase Inhibitors 3Session Date and Time: April 29, 2025, from 2:00 p.m.– 5:00 p.m. CTLocation: Poster Section 20Poster Board Number: 26\n*Presenter, corresponding author; 1Nuvalent, Inc., Cambridge, MA, USA\nAbout ZidesamtinibZidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and to drive deep, durable respons...